Back to EventsClinical Trial

New Trial: Wrist Extensor MEP Up-conditioning for Individuals With Incomplete Spinal Cord Injury

The purpose of this study is to examine the relationship between common clinical assessments and measurements of the function of brain-spinal cord-muscle connections, and to examine the effects of training a brain-spinal cord-muscle response in indiv...

Body Mind StateJuly 9, 20263 min read
New Trial: Wrist Extensor MEP Up-conditioning for Individuals With Incomplete Spinal Cord Injury

Trial Overview

NCT ID: NCT05321017 Phase: NA Enrollment Target: 5 Status: Recruiting

The purpose of this study is to examine the relationship between common clinical assessments and measurements of the function of brain-spinal cord-muscle connections, and to examine the effects of training a brain-spinal cord-muscle response in individuals with incomplete spinal cord injury. A transcranial magnetic stimulator (TMS) is used for examining brain-to-muscle pathways. This stimulator produces a magnetic field for a very short period of time and indirectly stimulates brain cells with little or no discomfort. The target muscle is the wrist extensor (extensor carpi radialis) muscle that bends the wrist back. It is hypothesized that training the wrist extensor muscle response to transcranial magnetic stimulation will increase the strength of the brain-to-muscle pathway, which will improve the ability to move the arm.

It is hoped that the results of this training study will help in developing therapy strategies for individuals, promoting better understanding of clinical assessments, and understanding treatments that aim to improve function recovery in people with spinal cord injury (SCI).

This study requires 30 visits, and each visit will last approximately 1.5 hours.

Why This Matters

[Draft — editorial context needed]

Source

Event Website
ClinicalTrials.gov
Visit Event →

Related

Stay Regulated

Regulate your nervous system from the inside out.

New research, honest product reviews, clinical trials, events, and funding news — delivered weekly, with zero sponsors or ads.